Skip to content


Daurismo (glasdegib) is a small molecule pharmaceutical. Glasdegib was first approved as Daurismo on 2018-11-21. It is used to treat myeloid leukemia acute in the USA. It has been approved in Europe to treat myeloid leukemia acute. The pharmaceutical is active against smoothened homolog. Daurismo's patent is valid until 2036-04-13 (FDA).
Trade Name Daurismo
Common Name Glasdegib
Indication myeloid leukemia acute
Drug Class Hedgehog signaling inhibitors
Get full access now